joyce o’shaughnessy, md: different mechanisms of action in eribulin
Published 8 years ago • 243 plays • Length 1:23
Download video MP4
Download video MP3
Similar videos
-
0:59
joyce o’shaughnessy, md: main indications for dose reduction with eribulin
-
1:39
joyce o’shaughnessy, md: efficacy data supporting the use of eribulin mesylate
-
1:11
joyce o’shaughnessy, md: candidacy for eribulin therapy
-
1:11
joyce o’shaughnessy, md: candidacy for eribulin therapy
-
1:59:33
addressing current questions and controversies in the management of metastatic breast cancer
-
14:21
genomic testing during breast cancer: should you have testing?
-
51:40
trop2-targeting adcs as new tools in the tnbc and hr /her2- breast cancer treatment arsenal
-
0:53
joyce o’shaughnessy, md: principle third-line options for patients with metastatic tnbc
-
2:08
dr. joyce o'shaughnessy on eribulin in metastatic breast cancer
-
6:09
dual moa for eribulin in breast cancer
-
1:56
joyce o’shaughnessy, md: treatment goals for patients with tnbc and multiple metastatic sites
-
1:22
dr. o'shaughnessy on the utility of capivasertib in targeting akt in breast cancer
-
1:20
dr. o’shaughnessy on eribulin as first-line therapy for metastatic her2-negative breast cancer
-
0:58
joyce o’shaughnessy, md: third-line options available to prolong life in tnbc
-
1:20
joyce o’shaughnessy, md: fourth-line considerations
-
5:48
preclinical observations on eribulin for breast cancer
-
5:25
eribulin in metastatic breast cancer
-
0:55
joyce o'shaughnessy, md discusses the importance of ibc 2018
-
6:38
molecular re-classification of breast cancer – part 2: joyce o'shaughnessy
-
0:58
joyce o’shaughnessy, md: third-line options to prolong life
-
2:42
eribulin as treatment for metastatic breast cancer
-
1:20
joyce o’shaughnessy, md: fourth-line considerations in metastatic tnbc
Clip.africa.com - Privacy-policy